|
|
||||||||
THIRST AND VOLUME, ELECTROLYTE HOMEOSTASIS
1Department of Zoology, University of Florida, Gainesville, Florida 32611; 3Department of Biology, Presbyterian College, Clinton, South Carolina 29325; and 2Mt. Desert Island Biological Laboratory, Salisbury Cove, Maine 04672
Submitted 22 May 2003 ; accepted in final form 17 November 2003
| ABSTRACT |
|---|
|
|
|---|
, and PGD2 did not affect the Isc. Our data are the first to suggest the importance of an ET-stimulated and NO-, O2--, and PGE2-mediated signaling axis that can modify active extrusion of NaCl across the killifish opercular epithelium and, by inference, the marine teleost gill epithelium. fish; gill transport; paracrine signaling
ET-like immunoreactivity also has been found in gill, heart, or neural tissue in all major groups of fishes, including agnathans, elasmobranchs, and teleosts (e.g., 27, 57), and a trout ET recently has been purified, sequenced, and synthesized (60). Infusion of either this peptide or human ET-1 produces a complex suite of cardiovascular responses in the trout, including a triphasic pressure change (pressor-depressor-pressor) in the dorsal aorta produced by changes in cardiac output, gill resistance, systemic resistance, and venous compliance (22). In vitro, ET-1 produces substantial constriction in blood vessels isolated from a variety of fish species (e.g., 16, 18, 55, 60). Pharmacological and physiological protocols have delineated both ETA and ETB receptors in fish blood vessels and gill tissue (e.g., 15, 16, 18).
NOS has been identified in central and peripheral neural tissue in a variety of fish species (e.g., 6, 20, 48-50) and also in neurons and epithelial cells in the gill of a catfish (e.g., 63) and the killifish (12). Prostanoids are produced in various tissues (including the gill, see below) in a variety of fish groups (e.g., 5, 29). NO (or an NO donor) is dilatory in teleost vessels (e.g., 39, 53) but constrictory in elasmobranch and hagfish vessels (e.g., 17, 18) and produces a biphasic response (constriction followed by dilation) in the lamprey ventral aorta (18). Prostanoids, however, are dilatory in vessels isolated from a variety of fish species (e.g., 14, 17-19), although it is unclear if the effector is PGI2 or PGE2, because of potential cross-reactivity with receptors. Despite these uncertainties, it is clear that modern representatives of the most ancient vertebrate lineages express the components of the paracrine signaling system that involves ET, NO, and prostanoids.
Both ETA and ETB receptors also have been identified in the mammalian kidney (e.g., 4) and ET produces natriuresis and diuresis at concentrations too low to affect systemic or renal hemodynamics (e.g., 47). These data suggest that ET can affect tubular transport as well as perfusion, and various studies have shown that ET inhibits salt and water reabsorption in the cortical and medullary thick ascending limbs (THAL) (e.g., 45), as well as the cortical and medullary collecting ducts (56). Like ET, NO can produce natriuresis and diuresis without concomitant changes in either glomerular filtration or renal blood flow, and the tubular effects appear to be primarily in the proximal tubule, THAL, and collecting duct (reviewed in 43). Moreover, NOS is expressed in renal tissue (e.g., 23, 35). Recent evidence suggests that superoxide (O2-) also may have measurable effects on THAL transport, either directly or via interactions with NO (e.g., 44). Prostanoids (generated by cyclooxygenase; COX) also can have epithelial as well as vascular effects in the kidney, inhibiting salt uptake in the THAL and collecting duct. The major effector appears to be PGE2, acting via EP1 and/or EP2 receptors, although receptors for other prostanoids (e.g., thromboxane A2, PGI2, PGF2
, and perhaps, PGD2) are also expressed in renal tissue (reviewed in 3). In addition, both COX-1 and COX-2 are expressed in renal tubules (e.g., 59). We are unaware of any published studies suggesting that the renal effects of ET can be linked to prostanoid production.
The gill is the primary site of osmoregulation in fishes, and the gill epithelium expresses many of the transport proteins found in the mammalian nephron. These transporters mediate NaCl excretion or uptake, depending on osmoregulatory needs of the fish (e.g., 32). For example, marine teleosts are hypoosmotic to their environment and use the gill epithelium to excrete the excess NaCl that diffuses inward across the gill, as well as that absorbed to drive intestinal uptake of water after ingestion of seawater to offset the osmotic loss of water across the gill epithelium (e.g., 24). There is good evidence that this NaCl transport system can be modulated by circulating hormones, such as cortisol, prolactin, growth hormone, and IGF, thyroid hormones, and arginine vasotocin (fish equivalent of vasopressin) and adrenergic neurotransmitters (e.g., 12). The role(s) of paracrine agents such as ET, NO, O2-, and prostanoids on teleost fish gill transport remain largely unexamined, however. The extant literature consists of two early studies (11, 58) that showed that prostanoids inhibit the short circuit current (Isc) across the opercular epithelium of the killifish (Fundulus heteroclitus). This tissue is the standard model of the branchial epithelium of marine teleost fishes because both tissues express the same cell types (e.g., mitochondrion-rich cells, pavement cells, and mucous cells), and the opercular epithelium can generate an Isc that is the result of net transport of Cl- across the epithelium (from basolateral to apical), with Na+ following passively via paracellular channels (26).
In the present study we examined the effects of ET, NO, and prostanoids on the Isc across the killifish opercular epithelium. Our data provide the first evidence for an ET to NO-O2--PGE2 axis of inhibition involving ETB receptors, NOS and COX-2. PGE2 appears to be the major effector in this axis, not NO, and the effect is mediated via EP1 and/or EP3 receptors. In addition, there is some evidence for a stimulatory, EP2-mediated receptor system. We found no evidence that other prostanoids (e.g., PGI2, thromboxane A2, PGF2
, or PGD2) are involved.
| MATERIALS AND METHODS |
|---|
|
|
|---|
5 g; both sexes) were collected by minnow trap in North East Creek, Mt. Desert Island, ME, during the summers of 1999-2002 and maintained in running seawater aquariums (16-20°C) for at least 24 h before death by cervical section and pithing. Gill operculae were removed, and the inner epithelium was removed by dissection under a microscope. The tissue was mounted over a 3 mm diameter aperture recessed in a Lucite plate and held in place by a small amount of silicone grease and a Lucite ring to minimize edge damage. The plate was inserted into a Lucite Ussing Chamber (Jim's Instruments) so that the 3 mm epithelial circle separated two chambers, each containing 2 ml of killifish Ringer (26) bubbled with 100% oxygen. Each chamber had ports to allow for aeration, solution addition, and removal and the insertion of Ag-AgCl2 electrodes to measure transepithelial electrical potential and produce an Isc. The output from these electrodes was monitored by a University of Iowa model 742C dual voltage clamp and recorded and saved by a Biopac MP100 data-acquisition system, using AcqKnowledge software on a Macintosh computer. Experiments were initiated only if and when a stable Isc (Isc > 50 µA/cm2) and resistance (>35 ohms/cm2) were reached, usually within 30 min. During the course of each experiment, electrical resistance was monitored by the automatic generation of a ±1 mV pulse every minute by the voltage clamp and recording the Isc deflection. No systematic changes in tissue resistance were observed in the course of any of the experiments. In all experiments, equal volumes of solution (agonist/inhibitor vs. carrier) were added to both sides of the tissues (experimental and control) to avoid volume and osmotic effects, because our initial studies confirmed that even a 2% osmolarity differential across this epithelium can affect the Isc (33).
Experimental chemicals were solubilized according to manufacturer's instructions, and the final concentrations used were determined from our earlier studies with these agonists/inhibitors or from published studies from other laboratories. In each case, the substance was dissolved in the appropriate solvent, subdivided, stored either frozen (-70 or -20°C) or at 4°C, and made up to the desired concentration by further dilution in the solvent and/or in the experimental medium (killifish Ringer) the day of the experiment. The final volume of agonist/inhibitor added ranged from 0.1 to 4% of the initial volume of the experimental medium. ET-1 (human) and SRXS6c (American Peptide, Sunnyvale, CA) were dissolved in 1% acetic acid and 50% DMSO, respectively, lyophilized (ET-1 only), and stored at -20°C. Sodium nitroprusside (Sigma, St. Louis, MO), TEMPOL (4-hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl; Sigma), and L-NAME (NG-nitro-L-arginine methyl ester; Cayman Chemical, Ann Arbor, MI) were dissolved in killifish Ringer and stored at 4°C; 1-benzylimidazole [1-(phenylmethyl)-1H-imadazole; Cayman] was dissolved in killifish Ringer and stored at -20°C. Indomethacin [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid; Sigma] was dissolved in 100 mM
-ethanol (3:1) and stored at 4°C. PGE2, carbaprostacyclin (6,9
-methylene-11
,15S-dihydroxy-prosta-5E,13E-dien-1-oic acid), PGD2, PGF2
, U-46619 (9,11-dideoxy-9
,11
-methanoepoxy-prosta-5Z, 13E-dien-1-oic acid), I-BOP {1S-[1
-
(Z),3
(1E,3S*),4
]-7-[3-[3-hydroxy-4-(4-iodophenoxy)]-1-butenyl]-7-oxabicyclo[2.2.1]hept-yl]-5-heptenoic acid}, SC550 [5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole], NS-398 {N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide}, butaprost (9-oxo-11
,16R-dihydroxy-17-cyclobutyl-prost-13E-en-1-oic acid, methyl ester), and sulprostone [N-(methylsulfonyl)-9oxo-11
,15R-dihydroxy-16-phenoxy-17,18,19,20-tetranor-prosta-5Z,13E-dien-1-amide] (all from Cayman Chemical) were dissolved in DMSO and stored at -20°C. Spermine NONOate {(Z)-1-[N-[3-aminopropyl]-N-[4-(3-aminopropylammonio)butyl]-amino]diazen-1-ium-1,2-diolate} was dissolved in 0.01 N NaOH on ice, purged with N2 and stored at -70°C.
The research protocols in this study were approved by IACUC committees at the University of Florida and the Mt. Desert Island Biological Laboratory.
All data are expressed as means ± SE. P values for statistical differences were calculated by the appropriate, two-tailed, paired or unpaired Student's t-tests, and concentration-dependence data were analyzed using repeated-measures ANOVA and the appropriate post-tests. In the data analysis of all putative inhibitor experiments, each tissue served as its own control when testing the effect of the inhibitor(s), but paired tissues (experimental vs. control) were compared when determining the effect of most of the putative inhibitors on the SRXS6c-mediated inhibition of the Isc. The exception was the COX-1 vs. COX-2 inhibitor study, where SC560 and NS-398 were applied to paired epithelia before SRXS6c was added, and the effect of either on the SRXS6c-mediated inhibition of the Isc was compared with the sum of the control effects of SRXS6c in the previous experiments (L-NAME, indomethacin, etc.). In this case, unpaired statistical analyses were used. In all cases, P < 0.05 was taken as significant. Specific statistical analyses were performed using Prism (GraphPad Software, San Diego, CA) and are indicated in the text and figure legends.
| RESULTS |
|---|
|
|
|---|
To confirm that the response of the Isc to ET-1 was concentration dependent, and to attempt to delineate the role of ETA vs. ETB receptors, the effects of the cumulative addition of ET-1 (agonist for both ETA and ETB receptors) or SRXS6c (ETB specific) were monitored. Both agonists produced a concentration-dependent inhibition of the Isc, becoming significant at 10-8 M and reaching 30-40% at 10-7 M in each case (Figs. 1B and 2). ET-1 and SRXS6c were equipotent at all concentrations tested. Because SRXS6c produced significant responses (suggesting the presence of ETB receptors), all subsequent experiments used SRXS6c as an ET agonist, to constrain the study to ETB-mediated effects.
|
|
Similar experiments determined the concentration dependence of the response of the Isc to either of two NO donors, SNP (Fig. 1C) and spermine NONOate (SPNO) or the prostanoids PGE2 (Fig. 1D) and carbaprostacyclin (CPR; stable analog of PGI2). Both NO donors (SNP and SPNO) produced a small, concentration-dependent inhibition of the Isc, reaching significance at 10-7 and 10-6 M, respectively (Fig. 3). The efficacy of both donors was the same at all concentrations. Both PGE2 and CPR also produced what appeared to be a concentration-dependent inhibition of the Isc, but only the effect of PGE2 reached statistical significance (Fig. 4). PGE2 was somewhat less effective than either ET or SRXS6c at equivalent concentrations.
|
|
Because these experiments determined that ET-1, PGE2, and NO donors produced concentration-dependent inhibition of the Isc, interactions between these putative signaling agents were examined by determining the effect of inhibition of either NOS by L-NAME or COX by indomethacin on the baseline (unstimulated) Isc as well as the SRXS6c-mediated inhibition of the Isc. These experiments used paired epithelia from the same animal, and either 10-4 M L-NAME or 10-5 M indomethacin was added to the experimental tissue, and the same volume of carrier was added to the control tissue. Initial studies determined that any response was relatively rapid, so after 15 min, 10-7 M SRXS6c was added to experimental tissue, and an equal volume of the carrier was added to the control tissue, and the Isc was recorded for an additional 30-60 min to equilibrium. Addition of L-NAME to the opercular epithelium stimulated the Isc slightly but significantly (experimental vs. control: 130 ± 10.2 vs. 113 ± 7.99 µA/cm2; n = 25; P < 0.01, paired t-test, 2 tailed). Subsequent addition of SRXS6c inhibited the Isc, but this inhibition was reduced by 17% in those tissues that had been pretreated with the NOS inhibitor (Table 1). Inhibition of COX by indomethacin did not affect the initial Isc (186 ± 37.5 vs. 191 ± 43.6 µA/cm2; n = 8; P = 0.79, paired t-test, 2 tailed), but it reduced the SRXS6c-mediated inhibition by nearly 90% (Table 1).
|
To determine if the effect of inhibition of NOS and COX (on baseline and SRXS6c inhibition) was additive, in another series of experiments both inhibitors were added to the tissue before the addition of SRXS6c. When L-NAME and indomethacin were added simultaneously, the initial Isc did not change (124 ± 21 vs. 124 ± 26 µA/cm2; n = 6; P = 0.99, paired t-test, 2 tailed), demonstrating that the inhibition of COX abolishes the stimulation of the Isc seen when L-NAME is added alone. The presence of both L-NAME and indomethacin inhibited the effect of subsequent addition of SRXS6c by 83% (Table 1), but the net effect was no greater than the effect of indomethacin alone.
Because NOS-mediated effects may be secondary to chemical interactions of NO with O2-, another series of experiments examined the effects of the spin trap TEMPOL (5 x 10 -3 M; a superoxide dismutase mimetic) on the baseline and SRXS6c-mediated inhibition of the Isc, as well as the effect of the simultaneous addition of L-NAME, indomethacin, and TEMPOL on these parameters. Addition of TEMPOL had no effect on the initial Isc across the epithelium (256 ± 47.7 vs. 260 ± 47.9 µA/cm2; n = 7; P = 0.39, paired t-test, 2 tailed), but it did reduce the SRXS6c-mediated inhibition by 34% (Table 1), twice the effect of inhibition of NOS by L-NAME (Table 1). Simultaneous addition of L-NAME, indomethacin, and TEMPOL did not affect the Isc (186 ± 53.4 vs.185 ± 49.2 µA/cm2; n = 6; P = 0.90, paired t-test, 2 tailed), but it completely inhibited the effect of subsequent addition of SRXS6c (Table 1; percent reduction by SRXS6c not different from zero; P = 0.14).
To attempt to differentiate between COX-1- and COX-2-mediated responses, the effects of SC560 (10-6 M; COX-1-specific inhibitor) and NS-398 (10-6 M; COX-2-specific inhibitor) on baseline Isc and SRXS6c-mediated inhibition were studied in another series of experiments. Addition of SC560 had no effect on the initial Isc (139 ± 25.5 vs. 138 ± 24.8 µA/cm2; n = 5; P = 0.89, paired t-test, 2 tailed), but the addition of NS-398 stimulated the Isc by 16% (150 ± 23.6 vs. 129 ± 20.8 µA/cm2; n = 5; P < 0.01; paired t-test, 2 tailed). Subsequent addition of SRXS6c inhibited the Isc, but previous inhibition of COX-1 reduced this inhibition by 46%, and inhibition of COX-2 reduced the effect by 90% (Table 1).
Because PGE2 can bind to any of four receptors (termed EP1-4), another series of experiments tested the effects of cumulative addition of either butaprost (EP2 specific) or sulprostone (EP1/3 specific; e.g., 3) on the Isc across paired opercular epithelia. Butaprost stimulated the Isc across the opercular epithelium in a concentration-dependent manner (reaching significance at 10-6 M); sulprostone produced the opposite effect on the Isc, reaching significance at 10-7 M (Fig. 5).
|
To test the efficacy of other prostanoids, putative agonists (carbaprostacyclin for PGI2, U-46619 and I-BOP for thromboxane A2, PGF2
, or PGD) were applied to opercular tissues using the same protocol as described for the PGE2-mediated concentration-dependence experiments. In addition, the ability of the thromboxane synthase inhibitor 1-benzylimidazole (10-5 M) to affect either baseline Isc or SRXS6c-mediated inhibition of the Isc was tested, using the protocol described for L-NAME, indomethacin, and TEMPOL. Neither of the putative TXA2 agonists (10-10-10-6 M U-46619 or I-BOP; n = 4) nor PGF2
or PGD2 (10-10-10-6 M; n = 5) produced any change in the Isc across the opercular epithelium (data not shown). Moreover, pretreatment with 1-benzylimidazole had no effect on the unstimulated Isc and did not blunt the SRXS6c-mediated inhibition of the Isc (P = 0.81, paired t-test, 2 tailed; n = 4; data not shown).
| DISCUSSION |
|---|
|
|
|---|
The fact that incubation with 10-4 M L-NAME produced a small, but significant, stimulation of the Isc suggests that tonic release of NO inhibits the Isc in the unstimulated tissue. However, if COX is also inhibited by the simultaneous addition of 10-5 M indomethacin and 10-4 M L-NAME, this stimulation is lost (Table 1). Thus another explanation of the L-NAME-mediated stimulation is that the unstimulated Isc is actually set by the sum of tonic, COX-mediated stimulation and NOS-mediated inhibition. However, inhibition of COX alone by preincubation with 10-5 indomethacin did not change the unstimulated Isc, contrary to the inhibition of the Isc one might expect if this model were correct. Moreover, inhibition of COX-2 alone, using the specific inhibitor NS-398, actually stimulated the Isc across the unstimulated tissue, suggesting the presence of a tonic, COX-mediated inhibition of the unstimulated Isc. Thus the current data suggest that both NO and a prostanoid may be tonically controlling the Isc across the unstimulated opercular epithelium, but the net roles of either signaling system cannot be determined from our data.
Despite our uncertainty about the relative roles of NO and prostanoids in tonic control, it is clear that both NO and prostanoids play a role in the response to stimulation of ETB receptors by SRXS6c, but prostanoids are obviously of greater importance (Table 1). Interestingly, published data suggest that prostanoids, not NO, are also the dominant endothelium-derived relaxing factor in the few fish species that have been studied (e.g., 17, 19, 41). Inhibition of either NOS or COX did not blunt the SRXS6c effect completely, and addition of both inhibitors simultaneously did not produce an additive response (Table 1), suggesting some interaction between the putative ET-NO and ET-PG axes and/or the presence of other components in the inhibition produced by activation of the ETB receptor by SRXS6c.
It has become clear that the role of NO in a variety of signaling pathways is at least partially controlled by its effectively instantaneous reaction (K
7 x 109 mol·l-1·s-1) with superoxide ions (O2-) to form peroxynitrite (OONO-), an especially toxic molecule (e.g., 30). These three molecules have been termed "the good, the bad, and the ugly" (e.g., 2) because the highly oxidative O2- and OONO- could produce physiological or pathophysiological responses directly, or merely because O2- removes NO from the system. The fact that the addition of the NO scavenger TEMPOL (5 x 10-3 M) blunted the effect of subsequent addition of SRXS6c by 34%, twice the effect of the addition of L-NAME, suggests that O2- itself plays a role in this signaling axis in the opercular epithelium (Table 1). Indeed, if TEMPOL, L-NAME, and indomethacin were added simultaneously to unstimulated tissue, the effect of subsequent addition of SRXS6c was completely inhibited (Table 1). Because TEMPOL reduced the effect of SRXS6c significantly more than L-NAME (the NO-dependent component), we hypothesize that O2- itself is inhibitory and can be produced by a pathway that is stimulated by ET/SRXS6c. In fact, a recent study demonstrated that ET generated O2- in a COX-dependent pathway after brain injury in newborn pigs (1), so it could be that the TEMPOL-dependent effect on the opercular epithelium is actually the sum of reduction of NO-O2- interactions and reduction of COX-generated O2-. It is notable that indomethacin alone reduced the SRXS6c effect to the same degree as indomethacin plus L-NAME or indomethacin plus L-NAME and TEMPOL, despite the fact that only the three inhibitors together produce inhibition that is statistically 100% (Table 1). This suggests that the COX-mediated prostanoid and O2- production is by far the dominant pathway in the operculum. It is clear that O2- production is not tonic, because TEMPOL did not affect the unstimulated Isc. Garvin's group (42) recently showed that addition of TEMPOL increases the inhibition of Cl- transport across the THAL of the rat loop of Henle produced by NO. The effect, however, appears to be via inhibition of a stimulatory response to O2- (rather than by removal of O2- and the subsequent stimulation of an NO-mediated inhibition), because exogenous production of O2- by the addition of xanthine oxidase/hypoxanthine stimulated Cl- transport across the THAL. They concluded, therefore, that O2- itself is stimulatory and not just a modulator of NO concentration (44).
The fact that pretreatment with NS-398, but not SC560, inhibited the Isc suggests that there may be a COX-2-mediated, tonic inhibition of the Isc, as is the case with NO (see above), in contrast to the indomethacin experiments that suggested that there is COX-mediated, tonic stimulation of the Isc. At this point, we cannot differentiate between these two alternatives, but these experiments do demonstrate that COX-mediated, tonic production of prostanoids may have effects on salt transport across the epithelium, and they also suggest that there may be different roles played by COX-1 vs. COX-2. Because inhibition of COX-2 was twice as effective in attenuating the SRXS6c-mediated inhibition of the Isc as inhibition of COX-1 (Table 1), it appears that both COX-1 and -2 are involved in the production of prostanoids after ETB stimulation in this tissue but that COX-2 is the major effector. The physiological importance of COX-1 and COX-2 has become appreciated in the past few years, and both are expressed in the rat nephron. For instance, a recent study has shown that COX-1 mRNA predominates in the glomerulus, distal tubule, and collecting duct, whereas COX-2 message is localized in the glomerulus and medullary THAL (59). The genes for the homologues of COX-1 and/or COX-2 have been cloned for the zebrafish (21), two trout species (46, 51), and dogfish shark (62), where the clone was amplified from the rectal gland, a functional analog of both the marine teleost gill and THAL of the mammalian nephron (e.g., 40, 52). The latter study found that the specific COX-2 inhibitor, NS-398, reduced the Cl- secretion rate of the shark rectal gland. This study suggests that prostanoids are stimulatory, rather than inhibitory, contrary to the present findings and what has been published in the renal literature (e.g., 3). On the other hand, stimulation of salt secretion by the shark rectal gland has the same effect as inhibition of salt uptake by the mammalian nephron: increased salt excretion.
Because the PGE2 receptors EP1 and EP3 predominate in mammalian renal tubules (e.g., 3), we attempted to differentiate between putative receptors in the killifish operculum by comparing the efficacy of the relatively specific agonists, butaprost (EP2), and sulprostone (EP1/3) in this system. The fact that butaprost produced a concentration-dependent stimulation and sulprostone produced a concentration-dependent inhibition (Fig. 5) suggests that EP2 and EP1 (and/or EP3) receptors are present and that release of PGE2 in the opercular epithelium can produce stimulation or inhibition, depending on the distribution of the respective receptors. Our data suggest that inhibitory receptors (EP1 and/or EP3) predominate, but the finding that the L-NAME-induced stimulation of the Isc is inhibited by the simultaneous addition of indomethacin suggests the presence of at least some stimulatory receptors. The actual receptors present could be identified by immunological or molecular techniques, as well as measurement of intracellular second messengers in the future. It is important to note, however, that early work on the killifish operculum demonstrated that the Isc could be stimulated by isoproterenol and inhibited by epinephrine and arterenol (10) and subsequent studies showed that the stimulation vs. inhibition is mediated by
-adrenergic and
-adrenergic receptors, respectively (37). In the killifish operculum,
-adrenergic receptors stimulate intracellular cAMP (38) and
-adrenergic receptors stimulate intracellular inositol triphosphate (34), parallel to at least EP2 and EP1, respectively. Thus the intracellular second messengers for the putative EP receptors that our data suggest appear to be present in the opercular epithelium.
The inability of thromboxane A2 agonists or PGF2
and PGD2 to elicit a change in the Isc across opercular skin suggests that, if receptors for these other prostanoids are present in this tissue, they play a minor role in modulating the transport of NaCl across this tissue. The inability of a TXA2 synthase inhibitor to reduce the SRXS6c-mediated reduction in the Isc supports this conclusion. The putative PGI2 agonist CPR was not as effective as PGE2 in inhibiting the Isc and the effect was not statistically significant (Fig. 4), which suggests that IP receptors are not important in this system. CPR, on the other hand, can also bind to the EP1 receptor (e.g., 3), and the PGE2 and the sulprostone data suggest that the EP1 or EP3 receptor mediates the majority of the inhibition seen after SRXS6c addition.
Our data are the first to suggest that ET can modulate salt transport across the killifish opercular epithelium. It is unclear what stimulus activates the ET receptor (presumably ETB); changes in plasma osmolarity or cardiovascular parameters, or other signaling agents, might be suggested to be the putative stimuli. Nevertheless, our data suggest that activation of the ETB receptor stimulates the production of NO, O2-, and prostanoids (probably PGE2), each of which inhibit the transport of NaCl. Prostanoids probably account for 70-90% of the inhibition, even when accounting for what appears to be a significant role for O2- in this system. It is not clear if NO plays a direct role or merely modifies O2- concentrations. COX-2 and COX-1 are both involved in the synthesis of the active prostanoid (as well as O2-), although COX-2 appears to play a much bigger role. Both stimulatory (EP2) and inhibitory (EP1/3) PGE receptors appear to be involved, although inhibition appears to be the most significant response. Our data do not allow a definitive model for the roles of NO and prostanoids in maintaining the unstimulated salt transport across this epithelium, but some aspects of this work provide evidence for some role for both effectors without any stimulation of the ET receptor. Figure 6 summarizes our current working hypothesis for the interactions between ET, NO, O2-, and PGE2 in inhibiting salt extrusion by the marine teleost gill epithelium, as modeled by the killifish opercular epithelium.
|
Perspectives
Because the opercular epithelium is the generally accepted model for the marine teleost fish branchial epithelium (see introduction), our data provide the first evidence that salt extrusion by the gill can be modulated by release of paracrine agents, in this case: ET, NO, O2-, and PGE2. Although we provide some evidence for a stimulatory prostanoid pathway, the bulk of the data suggest ET-stimulated and NO-O2--PGE2-mediated inhibition of salt transport. The result would be salt retention, because the gill is the dominant site of salt secretion in marine teleosts (e.g., 24). This signaling pathway, therefore, has the opposite final result from that found in the mammalian kidney, where ET, NO, and prostanoids are predominantly natriuretic because of inhibition of uptake in the renal tubules (see introduction). Because salt retention is important in fish in hypoosmotic environments (e.g., 13), we hypothesize that this paracrine modulating system is most important in freshwater species or euryhaline species as they enter freshwater. Indeed, gill tissue from the eel produces significantly more prostanoids (actually, PGD2 and 6-keto-F1
) after acclimation to freshwater (5). Interestingly, PGE2 concentrations were very low in this tissue, as well as trout gill, in this study, and no significant changes in PGE2 concentrations were seen in either species after acclimation to freshwater vs. seawater (5).
The cellular site of ET, NO, and prostanoid production (as well as cellular receptors) in the teleost gill is currently under investigation. Zaccone's group (64) demonstrated immunoreactivity for big-ET (ET prohormone) and NOS in what they term "neuroendocrine" cells in the branchial epithelium from a variety of teleosts and elasmobranchs. Our preliminary studies (12; and K. A. Hyndman, P. M. Piermarini, and D. H. Evans, unpublished observations) have localized immunoreactive NOS in cells distinct from the mitochondrion-rich cells (MRC; Cl- transporting) in both the killifish opercular epithelium and gill epithelium, but it is not clear if these are "neuroendocrine," mucous, or pavement cells. In the stingray gill, we find immunoreactive big-ET is in the MRC and COX is expressed in the filamental central venous sinus, but in the killifish gill big-ET can be localized to epithelial cells distinct from the MRC, and COX is seen in the MRC. Thus it is clear that species differences may exist; nevertheless, localization of the effectors and receptors for this new signaling axis is of great interest for comparative vertebrate physiology and may provide new insights into paracrine control axes in the mammalian kidney.
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
-adrenergic receptors and inositol 1,4,5-trisphosphate. J Exp Biol 201: 1959-1965, 1998.This article has been cited by other articles:
![]() |
M. G. Jonz and C. A. Nurse New developments on gill innervation: insights from a model vertebrate J. Exp. Biol., August 1, 2008; 211(15): 2371 - 2378. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Evans Teleost fish osmoregulation: what have we learned since August Krogh, Homer Smith, and Ancel Keys Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2008; 295(2): R704 - R713. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Evans, P. M. Piermarini, and K. P. Choe The Multifunctional Fish Gill: Dominant Site of Gas Exchange, Osmoregulation, Acid-Base Regulation, and Excretion of Nitrogenous Waste Physiol Rev, January 1, 2005; 85(1): 97 - 177. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |